Pascal’s wager
8 June 2020

The $140 bln drugmaker approached U.S. rival Gilead about a merger, Bloomberg reported. The combination lacks strategic logic and looks unlikely. CEO Pascal Soriot has done well for investors. The risk is AstraZeneca’s debt load, or his bigger ambitions, threaten that record.